Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × rrCLL × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 122 Melanoma 91 Neoplasms 81 Colorectal Neoplasms 62 Squamous Cell Carcinoma of Head and Neck 61 Neoplasm Metastasis 57 Triple Negative Breast Neoplasms 49 Carcinoma, Renal Cell 47 Breast Neoplasms 38 Lung Neoplasms 36 Ovarian Neoplasms 31 Pancreatic Neoplasms 30 Head and Neck Neoplasms 29 Stomach Neoplasms 28 Urinary Bladder Neoplasms 26 Carcinoma, Transitional Cell 26 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Endometrial Neoplasms 23 Uterine Cervical Neoplasms 22 Carcinoma, Hepatocellular 19 Esophageal Neoplasms 16 Recurrence 14 Prostatic Neoplasms 14 Lymphoma 14 Carcinoma, Squamous Cell 12 Small Cell Lung Carcinoma 11 Kidney Neoplasms 11 Advanced Solid Tumor 11 Solid Tumor 10 Sarcoma 10

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡